Turning a corner on HIV neutralization?

Microbes and Infection

Volumn 2, Issue 2, 2000, Pages 213-221

  Nunberg, Jack H ^a   Follis, Kathryn E ^a   Trahey, Meg ^a   Lacasse, Rachel A ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Antibodies; Envelope protein; Fusion; Human immunodeficiency virus; Vaccines; Virus neutralization

Indexed keywords

BETA CHEMOKINE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0034111659     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(00)00267-7     Document Type: Review

References (88)

1. Haigwood N.L., Zolla-Pazner S. Humoral immunity to HIV, SIV, and SHIV. AIDS. 12 (suppl A):1998;S121-S132.
2. Parren P.W.H.I., Moore J.P., Burton D.R., Sattentau Q.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 13 (suppl A):1999;S137-S162.
3. Montefiori D.C., Evans T.G. Workshop Summary: Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. Hum. Retrovirus. 15:1999;689-698.
4. Putney S.D., Matthews T.J., Robey W.G., Lynn D.L., et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science. 234:1986;139213-139215.
5. Rusche J.R., Javaherian K., Mc Danal C., Petro I., et al. Antibodies that inhibit fusion of HIV-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA. 85:1988;3198-3202.
6. Javaherian K., Langlois A.J., Larosa G.J., Profy A.T., et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 250:1990;1590-1593.
7. Haigwood N.L., Shuster J.R., Moore G.K., Lee H., et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retrovirus. 6:1990;855-869.
8. Montefiori D.C., Graham B.S., Kliks S., Wright P.F. NIAID AIDS Vaccine Clinical Trials Network, Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Invest. 12:1992;429-439.
9. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science. 233:1986;209-212.
10. Van Cott T.C., Polonis V.R., Loomis L.D., Michael N.L., Nara P.L., Birx D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retrovirus. 11:1995;1379-1390.
11. Stamatos N.M., Mascola J.R., Kalyanaraman V.S., Louder M.K., et al. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J. Virol. 72:1998;9656-9667.
12. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J.Y., et al. Prevention of HIV-1 infection in chimpanzees by pre- or post-exposure administration of gp120 V3 domain-specific monoclonal antibody. Nature. 355:1992;728-730.
13. White-Scharf M.E., Potts B.J., Smith L.M., Sokolowski K.A., et al. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology. 192:1993;197-206.
14. Wrin T., Loh T.P., Charron-Vennari J., Schuitemaker H., Nunberg J.H. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:1995;39-48.
15. Moore J.P., Cao Y., Qing L., Sattentau Q.J., et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
16. Conley A.J., Gorny M.K., KesslerùIi J.A., Boots L.J., et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:1994;6994-7000.
17. Hioe C.E., Xu S., Chigurupati P., Burda S., et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9:1997;1281-1290.
18. Pinter A., Honnen W.J., Kayman S.C., Trochev O., Wu Z. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine. 16:1998;1803-1811.
19. Posner M.R., Cavacini L.A., Emes C.L., Power J., Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune. Defic. Syndr. 6:1993;7-14.
20. Thali M., Furman C., Ho D.D., Robinson J., Tilley S., Pinter A., Sodroski J. Discontinuous., conserved neutralization epitopes overlap the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:1993;5635-5641.
21. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type. J. Virol. 68:1994;8312-8320.
22. Moore J.P., Ho D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS. 9 (suppl A):1995;S117-S136.
23. Montefiori D.C., Collman R.G., Fouts T.R., Zhou J.Y., et al. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J. Virol. 72:1998;1886-1893.
24. Trkola A., Ketas T., Kewalramani V.N., Endorf F., et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibody and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1998;1876-1885.
25. LaCasse R.A., Follis K.E., Moudgil T., Trahey M., et al. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J. Virol. 72:1998;2491-2495.
26. Follis K.E., Trahey M., LaCasse R.A., Nunberg J.H. Continued utilization of CCR5 coreceptor by a newly-adapted T-cell line-adapted isolate of human immunodeficiency virus type 1. J. Virol. 72:1998;7603-7608.
27. Cohen J. Jitters jeopardize AIDS vaccine trials [news]. Science. 262:1993;980-981.
28. Berman P.W., Matthews T.J., Riddle L., Champe M., et al. Neutralization of multiple laboratory and clinical isolates of HIV-1 by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:1992;4464-4469.
29. Nunberg J.H., Wrin T., Vennari J.C., Berman P.W., et al. Adjuvant formulations to increase the virus-neutralizing antibody response to HIV-1 rgp120 subunit vaccine. Brown F. Vaccines 94. 1994;23-27 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
30. Wrin T., Nunberg J.H. HIV-1 MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS. 8:1994;1622-1623.
31. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., et al. NIAID-AVEG, Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;340-348.
32. Kahn J.O., Steimer K.S., Baenziger J., Duliege A.M., et al. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1995;1343-1347.
33. Berman P.W., Gray A.M., Wrin T., Vennari J.C., et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176:1997;384-397.
34. Connor R.I., Korber B.T., Graham B.S., Hahn B.H., et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1998;1552-1576.
35. Beddows S., Lister S., Cheingsong R., Bruck C., Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:1999;1740-1745.
36. Van Cott T.C., Mascola J.R., Loomis-Price L.D., Sinangil F., et al. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J. Virol. 73:1999;4640-4650.
37. Van Cott T.C., Mascola J.R., Kaminski R.W., Kalyanaraman V., et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:1997;4319-4330.
38. Moore J.P., Cao Y., Leu J., Qin L., Korber B., Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:1996;427-444.
39. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., Ho D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:1996;445-458.
40. Weber J., Fenyo E.M., Beddows S., Kaleebu P., Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J. Virol. 70:1996;7827-7832.
41. Nyambi P.N., Nkengasong J., Lewi P., Andries K., et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:1996;6235-6243.
42. Ho D.D., Mc Keating J.A., Li X.L., Moudgil T., et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:1991;489-493.
43. Scott C.F. Jr, Silver S., Profy A.T., Putney S.D., et al. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type III MN strain. Proc. Natl. Acad. Sci. USA. 87:1990;8597-8601.
44. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:1993;635-643.
45. Muster T., Steindl F., Purtscher M., Trkola A., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:1993;6642-6647.
46. Trkola A., Purtscher M., Muster T., Ballaun C., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1996;1100-1108.
47. Burton D.R., Pyati J., Koduri R., Sharp S.J., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
48. D'Souza M.P., Livnat D., Bradac J.A., Bridges S.H., Aasw G.R.O.U.P. Collaborating Investigators, Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1997;1056-1062.
49. Trkola A., Pomales A.B., Yuan H., Korber B., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:1995;6609-6617.
50. Kessler J.A. III, Mc Kenna P.M., Emini E.A., Chan C.P., et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retrovirus. 13:1997;575-582.
51. Parren P.W., Ditzel H.J., Gulizia R.J., Binley J.M., et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS. 9:1995;F1-6.
52. Conley A.J., Kessler J.I. III, Boots L.J., Mc Kenna P.M., et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:1996;6751-6758.
53. Gauduin M.C., Parren P.W., Weir R., Barbas C.F., et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV- 1. Nature M. 3:1997;1389-1393.
54. Mascola J.R., Lewis M.G., Stiegler G., Harris D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:1999;4009-4018.
55. Moore J.P., Burton D.R. HIV-1 neutralizing antibodies: how full is the bottle. Nature M. 5:1999;142-144.
56. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, amd disease. Ann. Rev. Immunol. 17:1999;657-700.
57. Lacasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., Nunberg J.H. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science. 283:1999;357-362.
58. Tersmette M., Gruters R.A., De Wolf F., De Goede R.E.Y., et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63:1989;2118-2125.
59. Devico A., Silver A., Thronton A.M., Sarngadharan M.G., Pal R. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology. 218:1996;258-263.
60. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
61. Trkola A., Dragic T., Arthos J., Binley J.M., et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
62. Wu L., Gerard N.P., Wyatt R., Choe H., et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
63. Lapham C.K., Ouyang J., Chandrasekhar B., Nguyen N.Y., et al. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science. 274:1996;602-605.
64. Baik S.S., Doms R.W., Doranz B.J. HIV and SIV gp120 binding does not predict coreceptor function. Virology. 259:1999;267-273.
65. Sattentau Q.J., Moore J.P., Vignaux F., Traincard F., Poignard P. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:1993;7383-7393.
66. Furuta R.A., Wild C.T., Weng Y., Weiss C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nature Struct. Biol. 5:1998;276-279.
67. Bosch M.L., Earl P.L., Fargnoli K., Picciafuoco S., et al. Identification of the fusion peptide of primate immunodeficiency. Proc. Natl. Acad. Sci. USA. 244:1989;694-697.
68. Freed E.O., Myers D.J., Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. USA. 87:1990;4650-4654.
69. Martin I., Schaal H., Scheid A., Ruysschaert J.M. Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer. J. Virol. 70:1996;298-304.
70. Delahunty M.D., Rhee I., Freed E.O., Bonifacino J.S. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. Virology. 218:1996;94-102.
71. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
72. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
73. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV gp41. Nature. 387:1997;426-430.
74. Malashkevich V.N., Chan D.C., Chutkowski C.T., Kim P.S. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. USA. 95:1998;9134-9139.
75. Weissenhorn W., Calder L.J., Wharton S.A., Skehel J.J., Wiley D.C. The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc. Natl. Acad. Sci. USA. 95:1998;6032-6036.
76. Young J.K., Li D., Abramowitz M.C., Morrison T.G. Interaction of peptides with sequences from the Newcastle Disease Virus fusion protein heptad repeat regions. J. Virol. 73:1999;5945-5956.
77. Wild C., Oas T., Mc Danal C., Bolognesi D., Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA. 89:1992;10537-10541.
78. Kilby J.M., Hopkins S., Venetta T.M., Dimassimo B., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature M. 4:1998;1302-1307.
79. Thali M., Moore J.P., Furman C., Charles M., et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:1993;3978-3988.
80. Brown A.E., Mc Neil J.G. HIV vaccine development: a subtype E-specific strategy. Southeast Asian J. Trop. Med. Public Health. 29:1998;377-382.
81. Cao H., Kanki P., Sankale J.L., Dieng A., et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 71:1997;8615-8623.
82. Parren P.W., Wang M., Trkola A., Binley J.M., et al. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J. Virol. 72:1998;10270-10274.
83. Poignard P., Sabbe R., Picchio G.R., Wang M., et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 10:1999;431-438.
84. Haigwood N.L., Watson A., Sutton W.F., Mc Clure J., et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:1996;107-114.
85. Shibata R., Igarashi T., Haigwood N., Buckler A., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature M. 5:1999;204-210.
86. Stiehm E.R., Lambert J.S., Mofenson L.M., Bethel J., et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J. Infect. Dis. 179:1999;567-575.
87. WHO Network for HIV Isolation and Characterization, HIV type 1variation in who-sponsored vaccine evaluation sites: genetic screening sequence analysis and preliminary biological characterization of selected viral strains. AIDS Res. Hum. Retrovirus. 10:1994;1327-1343.
88. Deng H., Liu R., Ellmeier W., Choe S., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.